JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
ADNOC Gas Targets Up to $4B Profit in 2026 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Airbus Joins Air India A320 Altitude Drop Probe 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
AstraZeneca PLC (LON:AZN) announced plans to transfer its U.S. trading venue from Nasdaq to the New York Stock Exchange (NYSE), a move designed to broaden access to global investors and enhance long-term growth opportunities. The Anglo-Swedish pharmaceutical giant emphasized that it will remain headquartered and tax resident in the United Kingdom, while continuing to maintain listings in London and Stockholm.
Following the announcement, AstraZeneca shares gained 1.5% in early London trading, reflecting investor optimism about the transition. Chair Michel Demare noted the strategic importance of the shift, explaining that a harmonized global listing structure will help support sustainable growth and provide exposure to a more diverse mix of institutional and retail investors, particularly within the U.S. market.
The decision comes amid mounting pressure on the U.K. equity market as major corporations seek higher valuations abroad. Several well-known firms, including Unilever with its ice cream business spin-off and commodities group Glencore, have explored alternatives to London. AstraZeneca’s move underscores this broader trend of companies reassessing the appeal of the London Stock Exchange.
Despite speculation earlier this year that AstraZeneca might abandon its London presence entirely, the company confirmed it remains committed to its U.K. base. However, the drugmaker has scaled back certain domestic investments, including shelving a planned £200 million expansion of its Cambridge research facility, citing challenging business conditions in the country.
Political and regulatory pressures are also influencing AstraZeneca’s global strategy. With the U.S. government taking a tougher stance on the pharmaceutical industry, including calls for greater domestic investment, AstraZeneca aims to balance market access with operational flexibility. The proposal still requires shareholder approval, with a vote scheduled for November 3.
By securing a NYSE listing while retaining its European bases, AstraZeneca is positioning itself to attract a wider pool of global investors, strengthen its market presence, and support its long-term strategy for sustainable growth.
